---
title: "Definitive Healthcare Corp. Stock 12‑Month Price Target Cut to $2.2, Implies 233% Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291153169.md"
description: "Definitive Healthcare Corp.'s average 12-month price target was lowered from $2.67 to $2.2 by six analysts, with forecasts ranging from $0.7 to $3. Despite the cut, the updated target implies a 233% upside based on the June 26 closing price. The consensus rating remains 'Hold' across ten covering analysts, comprising two buys, six holds, and two sells."
datetime: "2026-06-29T13:20:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291153169.md)
  - [en](https://longbridge.com/en/news/291153169.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291153169.md)
generator: "portal-rs"
---

# Definitive Healthcare Corp. Stock 12‑Month Price Target Cut to $2.2, Implies 233% Upside

-   According to estimates from 6 analysts, Definitive Healthcare Corp. stock's average price target has fallen from $2.67 to $2.2, with forecasts ranging from $0.7 to $3 per share
-   Based on the Jun. 26 closing price, the updated target implies approximately 233% potential upside
-   Consensus rating remains at “Hold” across 10 covering analysts, with 2 Buys, 6 Holds and 2 Sells

Explore more price target data and ratings for Definitive Healthcare Corp. on the , and track all previous and future analyst recommendations for Definitive Healthcare Corp. in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [DH.US](https://longbridge.com/en/quote/DH.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Definitive Healthcare Q2 revenue slightly misses estimates despite customer gains](https://longbridge.com/en/news/295445972.md)
- [Does Interparfums’ (IPAR) Earnings Upgrade Hint At Deeper Strength In Its Profit Model?](https://longbridge.com/en/news/296564505.md)
- [CONMED (CNMD) Could Be 8% Overvalued Following Its Recent Rebound](https://longbridge.com/en/news/296318744.md)
- [Arcus Biosciences (RCUS) Stock Looks Strong On Returns But Stretched On Sales](https://longbridge.com/en/news/296529363.md)
- [Constellation Acquisition Corp I delays Q2 10-Q filing after disclosure review drags](https://longbridge.com/en/news/296141804.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**